What does this research mean for the field?

Ellagic acid sensitizes triple-negative breast cancer tumors to radiotherapy by targeting the CARM1-CDK4 axis while simultaneously protecting the heart from radiation-induced injury. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

March 3, 2026Open Access

A radiotherapeutic paradox: ellagic acid sensitizes tumors while attenuating radiation-induced myocardial injury

Key Points

Tumors exhibited increased sensitivity when treated with ellagic acid, demonstrating a promising dual function.
The analysis specifically highlighted modifications in the CARM1-CDK4 axis as a key mechanism involved in sensitization.

Structured PICO

Population

Triple-negative breast cancer (TNBC) models undergoing radiotherapy

Intervention

Ellagic acid

Outcome

Tumor sensitization and protection against radiation-induced myocardial injury

Ellagic acid represents a promising adjuvant in TNBC radiotherapy that may simultaneously enhance tumor sensitization and prevent radiation-induced cardiotoxicity.

Abstract

Ellagic acid exhibits a unique dual function in TNBC radiotherapy: it sensitizes tumors by targeting the CARM1-CDK4 axis while protecting the heart through potent antioxidant activity. These findings position ellagic acid as a promising adjuvant candidate to enhance therapeutic efficacy and safety in TNBC radiotherapy.

KI fragen

Bookmark

View Full Paper

Cite This Study

Li et al. (Wed,) studied this question.

synapsesocial.com/papers/69a75c21c6e9836116a24a28 https://doi.org/https://doi.org/10.3389/fonc.2026.1652278

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark

View Full Paper